319 related articles for article (PubMed ID: 32394753)
1. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
[TBL] [Abstract][Full Text] [Related]
3. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
Shin SC; Vickman RE; Filimon B; Yang Y; Hu Z; Mangold KA; Prabhakar BS; Schreiber H; Xu W
Cancer Gene Ther; 2024 Apr; 31(4):574-585. PubMed ID: 38267626
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.
Hu Z; Gerseny H; Zhang Z; Chen YJ; Berg A; Zhang Z; Stock S; Seth P
Mol Ther; 2011 Sep; 19(9):1609-18. PubMed ID: 21712815
[TBL] [Abstract][Full Text] [Related]
6. The Safety and Efficacy of Systemic Delivery of a New Liver-de-targeted TGFβ Signaling Inhibiting Adenovirus in an Immunocompetent Triple Negative Mouse Mammary Tumor Model.
Xu W; Shin SC; Vickman R; Filimon B; Yang Y; Hu Z; Mangold K; Prabhakar B; Schreiber H
Res Sq; 2023 Sep; ():. PubMed ID: 37790556
[TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
8. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
[TBL] [Abstract][Full Text] [Related]
9. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.
Xu W; Zhang Z; Yang Y; Hu Z; Wang CH; Morgan M; Wu Y; Hutten R; Xiao X; Stock S; Guise T; Prabhakar BS; Brendler C; Seth P
Mol Ther; 2014 Aug; 22(8):1504-1517. PubMed ID: 24791939
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
Hu Z; Zhang Z; Guise T; Seth P
Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
[TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.
Hu Z; Gupta J; Zhang Z; Gerseny H; Berg A; Chen YJ; Zhang Z; Du H; Brendler CB; Xiao X; Pienta KJ; Guise T; Lee C; Stern PH; Stock S; Seth P
Hum Gene Ther; 2012 Aug; 23(8):871-82. PubMed ID: 22551458
[TBL] [Abstract][Full Text] [Related]
12. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
Seth P; Wang ZG; Pister A; Zafar MB; Kim S; Guise T; Wakefield L
Hum Gene Ther; 2006 Nov; 17(11):1152-60. PubMed ID: 17032151
[TBL] [Abstract][Full Text] [Related]
13. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
Yang Y; Xu W; Neill T; Hu Z; Wang CH; Xiao X; Stock SR; Guise T; Yun CO; Brendler CB; Iozzo RV; Seth P
Hum Gene Ther; 2015 Dec; 26(12):813-25. PubMed ID: 26467629
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Zhao H; Wang H; Kong F; Xu W; Wang T; Xiao F; Wang L; Huang D; Seth P; Yang Y; Wang H
Hum Gene Ther; 2019 Feb; 30(2):197-210. PubMed ID: 30032645
[TBL] [Abstract][Full Text] [Related]
16. An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation.
Wang ZG; Zhao W; Ramachandra M; Seth P
Mol Cancer Ther; 2006 Feb; 5(2):367-73. PubMed ID: 16505111
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
[TBL] [Abstract][Full Text] [Related]
18. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Hakkarainen T; Särkioja M; Lehenkari P; Miettinen S; Ylikomi T; Suuronen R; Desmond RA; Kanerva A; Hemminki A
Hum Gene Ther; 2007 Jul; 18(7):627-41. PubMed ID: 17604566
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
20. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.
Shayakhmetov DM; Li ZY; Ni S; Lieber A
Cancer Res; 2002 Feb; 62(4):1063-8. PubMed ID: 11861383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
